News
CLVS
--
0.00%
--
Clovis Oncology Rises 3.64% on Heavy Volume: Watch For Potential Pullback
Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.36 to a high of $4.57. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $4.50 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/25 17:59
Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Clovis Oncology's (CLVS) -2.05% PM, existing holder of its 4.50% convertible senior notes due 2024 has chosen to exercise its option to purchase an additional $7.5M principal amount of the New
Seekingalpha · 11/25 11:46
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.5
Business Wire · 11/24 23:06
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that pursuant to the terms of that previously announced Exchange and Purchase Agreement, dated as of November 4, 2020, by and between Clovis Oncology and an existing holder of its securities named therein (the "Holder") relating to the offering of the Company's new series of 4.50% Convertible Senior Notes due 2024 (the "New 2024 Notes"), such Holder has elected to exercise its option to purchase an additional $7.5 million aggregate principal amount of the New 2024 Notes on the same terms. The settlement of the option is expected to occur on November 27, 2020, subject to customary closing conditions. Following the closing, there will be a total of $57.5 million aggregate principal amount of the New 2024 Notes outstanding.
BusinessWire · 11/24 20:06
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Business Wire · 11/20 13:00
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a pre-recorded fireside chat with President and Chief Executive Officer Patrick J. Mahaffy will be available next week for replay as part of the Piper Sandler 32nd Annual Healthcare Conference. The virtual conference, which takes place November 30 to December 3, 2020, incorporates a library of pre-recorded fireside chat presentations with presenting companies available on Monday, November 23, 2020 at 10:00 a.m. Eastern time.
BusinessWire · 11/20 10:00
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
Zacks · 11/06 15:43
ACB, BLUE, SD and UPWK among midday movers
Gainers: Altus Midstream (ALTM) +150%.Hall of Fame Resort & Entertainment (HOFV) +118%.Oncternal Therapeutics (ONCT) +82%.Upwork (UPWK) +41%.Aptevo Therapeutics (APVO) +40%.Resideo Technologies (REZI) +35%.Aurora Cannabis (ACB) +34%.Kaixin Auto (KXIN) +33%.Falcon Minerals (FLMN) +28%.SandRidge Energy
Seekingalpha · 11/05 17:43
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Business Wire · 11/05 13:02
Clovis Oncology Announces Third Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year.
BusinessWire · 11/05 10:05
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on November 4, 2020 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of its currently outstanding 4.50% Convertible Senior Notes due 2024 (the "Existing 2024 Notes"). Pursuant to the Agreement, in exchange for $64,842,000 aggregate principal amount of Existing 2024 Notes held by the holder (which is currently convertible into approximately 8.9 million shares of common stock), Clovis Oncology has agreed to issue to the holder a number of shares of the Company's common stock (the "Exchanged Shares") utilizing an exchange ratio that is based in part on the daily volume-weighted average prices ("VWAPs") per share of Clovis Oncology's common stock during a seven-trading day pricing period following execution of the Agreement.
BusinessWire · 11/05 10:02
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company's results in greater detail.
BusinessWire · 10/20 20:05
Clovis Oncology Set to Possibly Rebound After Yesterday's Selloff of 3.01%
Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $5.73 to a high of $6.03. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $5.82 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Comtex SmarTrend(R) · 10/19 18:13
Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc (CLVS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 10/15 03:15
Most Heavily Shorted Stocks: October 2020
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding.An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers.We analyze key trends and how to best interpret the short interest data.
Seekingalpha · 10/14 17:38
How Much Is Clovis Oncology, Inc. (NASDAQ:CLVS) Paying Its CEO?
This article will reflect on the compensation paid to Patrick Mahaffy who has served as CEO of Clovis Oncology, Inc...
Simply Wall St. · 10/13 11:47
The Top Mid-Cap Stocks To Target On Down Days
The best-rated mid-cap sector is consumer goods.The top scoring industry is specialty retail.Churchill Downs, Simply Good Foods, and Wolverine World Wide are among the best scoring stocks this week.
Seekingalpha · 10/03 11:04
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
, /PRNewswire/ -- The global market for brain tumor therapeutics is projected to see significant growth over the next several years. A brain tumor is an abnormal growth of tissue in the brain or central spine that can disrupt proper brain function. Although there are standard treatments such as surgery and chemotherapy, targeted therapy is on the rise and is the focus of much of the R&D in the market. Targeted therapy is a treatment that targets the tumor's specific genes, proteins, or the tissue environment that contributes to a tumor's growth and survival. This type of treatment blocks the growth and spread of tumor cells and limits the damage to healthy cells. A by Grand View in 2015 said that the global brain tumor diagnosis and therapeutics market size was valued at and was expected to grow at a CAGR of 8.1%through 2025. The rising prevalence of such cancer and the growing geriatric population are key drivers expected to nurture growth of the brain tumor diagnosis market worldwide. Active biotech and pharma companies in the markets this week include (NASDAQ: MBRX), (NASDAQ: CLVS), (NYSE: GSK), (NYSE: MRK), (NASDAQ: AZN).
PR Newswire - PRF · 10/01 12:30
Clovis Oncology (CLVS) Investor Presentation - Slideshow
The following slide deck was published by Clovis Oncology, Inc. in conjunction with this event.
Seekingalpha · 09/22 21:36
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 09/18 14:56
Webull provides a variety of real-time CLVS stock news. You can receive the latest news about Clovis Oncology through multiple platforms. This information may help you make smarter investment decisions.
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
More